ULSC for Facioscapulohumeral Muscular Dystrophy
exploratorydrug program · high · Mon Dec 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety and preliminary efficacy of umbilical cord lining-derived stem cells in relieving symptoms of Facioscapulohumeral Muscular Dystrophy type 1 or 2.
Randomized placebo-controlled clinical trial using repeated IV infusions; participants receive two doses of 100 million ULSC cells and two placebo doses in sequence.
ClinicalTrials.gov record for Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy published on 2025-12-01.
ULSC for COVID-19 ARDS
phase 2drug program · high · Wed Dec 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate safety and potential efficacy of allogeneic umbilical cord lining stem cells in hospitalized patients with acute respiratory distress syndrome due to COVID-19.
Sequential Phase 1 and Phase 2a clinical trial of IV allogeneic ULSC, described as umbilical cord tissue-derived mesenchymal stem cells.
ClinicalTrials.gov record published on 2020-12-23.
Activated NK cell senescence program
exploratoryresearch program · high
Investigate whether propagated and activated natural killer cells can reduce senescent cells and immunosenescence markers.
Ex vivo propagation and activation of autologous NK cells from 5 patients, followed by assessment of senescence markers including p16 and beta-galactosidase in human PBMCs and inflammatory cytokine panels.
Study published in 2022 showing activated NK cells decreased senescence markers in vitro.
Activated NK cells decreased senescent cells and immunosenescence markers in human PBMCs; cytokine data suggested a potential role in reducing aging-related inflammatory response.
Restem-L for Idiopathic Inflammatory Myopathies
phase 2drug program · high
Treat Idiopathic Inflammatory Myopathies by modulating inflammatory immune response and supporting tissue repair.
Off-the-shelf umbilical cord lining modified progenitor cell therapeutic administered as a cellular therapy.
Reported clinical benefit in Idiopathic Inflammatory Myopathies, received FDA Fast Track and Orphan Drug Designations, and is preparing for Phase 2/3 clinical trials.
Site analysis states Restem-L demonstrated clinical benefit in Idiopathic Inflammatory Myopathies.
rESTEM-x
undiscloseddrug program · low
Undisclosed pipeline program listed by Restem.
Not specified in the supplied material beyond inclusion in Restem's pipeline context for off-the-shelf cellular therapeutics.
Listed in Restem pipeline analysis.
Rheumatoid Arthritis cell therapy program
undiscloseddrug program · low
Target Rheumatoid Arthritis as an inflammatory-driven disease indication.
Not specified in the supplied material; listed in the context of Restem's UMPC/NK cell therapeutic pipeline.
Listed in Restem pipeline analysis.
ULSC for LVAD-associated bleeding
phase 1research program · high
Evaluate safety, tolerability, and early efficacy signals of umbilical cord lining stem cells in LVAD recipients with bleeding complications.
3+3 pilot study in 9 patients using escalating IV ULSC doses; assessed infusion safety, immune sensitization, angiopoietin markers, and fecal blood content.
Pilot study results published in 2024.
No infusion-related adverse events, toxic responses, or immune sensitization were observed. Some patients showed angiogenic stabilization and quantitative fecal immunochemical testing suggested reduced stool blood content by day 30.
Umbilical Cord Lining Modified Progenitor Cell platform
undisclosedplatform · medium
Develop off-the-shelf cellular therapeutics for inflammatory-driven diseases through immune modulation and tissue repair.
Proprietary umbilical cord lining modified progenitor cell platform with end-to-end manufacturing capabilities for off-the-shelf cellular therapeutics.
Platform described on Restem site as supported by 17 years of research, a leading IP portfolio, and manufacturing capabilities.
